1Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J]. Kidney Int, 2002, 62(1): 245-252.
2Bailie GR. Calcium and phosphorus management in chronic kidney disease: Challenges and trends[J]. Formulary, 2004, 39(7): 358-365.
3National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis, 2003, 42(4 Suppl 3) :S1-S201.
4Schomig M, Ritz E. Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives-calcimimetics[J]. Nephrol Dial Transplant, 2000, 15(Suppl 5): 30-31.
1Moe SM, Kraus MA, Gassensmith GM, et al. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant, 1998, 13: 1234-1241.
2Heaf JG, Lokkegard H. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age. J Nephrol, 1998, 11: 203-210.
3BrandiL, EgfjordM, OlgaardK. Pharmacokinetics of l, 25(OH) 2D3and lalpha(OH) D3 in normal and uremic men. Nephrol Dial Transplant, 2002, 17: 829-842.
4Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int, 1997, 51: 328-336.
5Fukagawa M, Kazama JJ, Shigematsu T. Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol Dial Transplant, 2002, 17: 1553-1557.
6Wang X, Sun B, Zhou F, et al. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin Med J, 2001, 114: 410-414.
7Ardissino G, Schmitt CP, Testa S, et al. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. Pediatr Nephrol, 2000, 14: 664-668.
8Herrmann P, Ritz E, Schmidt-Gayk H, et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron, 1994,67: 48-53.
9Norris KC. Avoiding the risk of secondary hyperparathyroidsim in chronic renal failure: a new approach, and a review. Dial Transplant, 2001,30: 355-367.
10Jara A, Chacon C, Valdivieso A, et al. Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia. Nephrol Dial Transplant, 2001, 16:1009-1016.
7Ito H,Ogata H,Yamamoto M,et al.Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism:a randomized,crossover trial[J].Clin Nephrol,2009,71:660-668.
8National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney Dis,2003,42:S1-201.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis.2003:42(4 Suppl 3):S1-201.
9Levey AS,Coresh J,Balk E.et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Ann Intern Med,2003,139:137-147.
10Raggi P,Boulay A,Chasan-Taber S,et al.Cardiac calcification in adult hemodialysis patients.A link between end-stage renal disease and cardiovascular disease?[J].J AM COLL Cardiol,2002,39:695-701.
